Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAC and Exemestane as Neoadjuvant Chemotherapy in Breast Cancer
NCT01648608Phase 3Unknown
- Sponsor
- Tianjin Medical University
- Start
- Jan 2012
- Primary completion
- Dec 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of exemestane in breast cancer, sponsored by Tianjin Medical University. Primary endpoint: Therapeutic Assessment at 6 months. Status: unknown.
02
Drugs
exemestane
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT01648608.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01648608.